Rare variant associations with birth weight identify genes involved in adipose tissue regulation, placental function and insulin-like growth factor signalling 1 2 3

4

Katherine A. Kentistou^{*1}, Brandon E. M. Lim^{*2}, Lena R. Kaisinger^{*1}, Valgerdur Steinthorsdottir³, Luke N Sharp², Kashyap A. Patel², Vinicius Tragante³, Gareth Hawkes², Eugene J. Gardner¹, Thorhildur Olafsdottir³, Andrew R. Wood², Yajie Zhao¹, Gudmar Thorleifsson³, Felix R. Day¹, Susan E. Ozanne⁶, Andrew T. Hattersley², Stephen O'Rahilly⁶, Kari Stefansson^{3,4}, Ken K. Ong^{*1,5}, Robin N. Beaumont^{*2}, John R. B. Perry*^{1,6}, Rachel M. Freathy*² 5 6 7 8 9 10

- 11
- **1.** MRC Epidemiology Unit, Box 285 Institute of Metabolic Science, University of Cambridge 12
- School of Clinical Medicine, Cambridge CB2 0QQ, UK 13
- **2.** Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, 14
- University of Exeter, Exeter, UK 15
- **3.** deCODE genetics/Amgen, Inc., 102 Reykjavik, Iceland 16
- **4.** Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland 17
- **5.** Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK 18
- **6.** MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge 19
- School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK 20
- ***** These authors contributed equally to this work. 21

Abstract 22

Investigating the genetic factors influencing human birth weight may lead to biological insights into fetal growth and long-term health. Genome-wide association studies of birth weight have highlighted associated variants in more than 200 regions of the genome, but the causal genes are mostly unknown. Rare genetic variants with robust evidence of association are more likely to point to causal genes, but to date, only a few rare variants are known to influence birth weight. We aimed to identify genes that harbour rare variants that impact birth weight when carried by either the fetus or the mother, by analysing whole exome sequence data in UK Biobank participants. 23 24 25 26 27 28 29 30

31

We annotated rare (minor allele frequency <0.1%) protein-truncating or high impact missense variants on whole exome sequence data in up to 234,675 participants with data on their own birth weight (fetal variants), and up to 181,883 mothers who reported the birth weight of their first child (maternal variants). Variants within each gene were collapsed to perform gene burden tests and for each associated gene, we compared the observed fetal and maternal effects. We identified 8 genes with evidence of rare fetal variant effects on birth weight, of which 2 also showed maternal effects. One additional gene showed evidence of maternal effects only. We observed 10/11 directionally concordant associations in an independent sample of up to 45,622 individuals (sign test *P*=0.01). 32 33 34 35 36 37 38 39 40

41

Of the genes identified, *IGF1R* and *PAPPA2* (fetal and maternal-acting) have known roles in insulin-like growth factor bioavailability and signalling. *PPARG, INHBE* and *ACVR1C* (all fetal-acting) have known roles in adipose tissue regulation and rare variants in the latter two also showed associations with favourable adiposity patterns in adults. We highlight the dual role of *PPARG* in both adipocyte differentiation and placental angiogenesis. *NOS3, NRK,* and *ADAMTS8* (fetal and maternal-acting) have been implicated in both placental function and hypertension. 42 43 44 45 46 47 48

49

Analysis of rare coding variants has identified regulators of fetal adipose tissue and fetoplacental angiogenesis as determinants of birth weight, as well as further evidence for the role of insulin-like growth factors. 50 51 52

Introduction 53

An improved understanding of the genetic contribution to birth weight may highlight mechanisms relevant to fetal growth restriction or overgrowth, as well as links between fetal growth and later disease^{[1](https://www.zotero.org/google-docs/?P04519)}. Studies of rare, monogenic forms of diabetes have highlighted the key role of fetal insulin, since rare single gene mutations in the fetus that reduce insulin secretion are generally associated with a reduced birth weight. These include mutations that cause neonatal diabetes, where the severity of the insulin secretory defect correlates with the degree of reduction in birth weight^{[2](https://www.zotero.org/google-docs/?CUfuCi)}. In babies who produce no insulin at all due to pancreatic agenesis, or to complete loss-of-function (LoF) mutations in the insulin gene, birth weights are 50% of those of a healthy term baby^{[3](https://www.zotero.org/google-docs/?HNoYHm)}. 54 55 56 57 58 59 60 61 62

63

Family studies of mutations in the *GCK* gene have demonstrated the role of maternal genetic variants, which may influence birth weight independently of variants inherited by the fetus. Maternal heterozygous mutations in *GCK,* which reduce glucose sensing and cause fasting glucose to be regulated at a higher set-point, result in greater maternal glucose availability to the fetus, as glucose crosses the placenta. This causes the fetus, if it does not carry the mutation, to produce more fetal insulin and grow bigger in response^{[4](https://www.zotero.org/google-docs/?TGEOVL)}. Conversely, if the fetus carries a *GCK* mutation, its ability to sense the increase in glucose is impaired, causing reduced fetal insulin secretion and concomitant reduced fetal growth. 64 65 66 67 68 69 70 71

72

Genome-wide association studies of birth weight have identified >200 regions of the genome where common variants (minor allele frequency (MAF) >1%) are associated with birth weight^{[5,6](https://www.zotero.org/google-docs/?ITc4vY)}. Variants at the identified loci influence birth weight by direct effects of the fetal genotype, indirect effects of the maternal genotype acting on the intrauterine environment, or a combination of the two. Most of these variants likely influence growth via mechanisms that are independent of fetal insulin secretion^{[7](https://www.zotero.org/google-docs/?Gl3OFe)}. Parent-of-origin effects in the fetus have been observed at several birth weight loci^{[6](https://www.zotero.org/google-docs/?dy5L7K)}. However, the causal genes at the vast majority of identified loci are unknown. 73 74 75 76 77 78 79 80

81

Whole exome sequence (WES) data in biobank-scale studies offer the opportunity to identify genes that are causally related to birth weight, and the potential to uncover new mechanisms of importance for the regulation of fetal growth. We performed exome-wide association studies (ExWAS) of rare variant (MAF <0.01) gene burden with birth weight in up to 234,675 UK Biobank participants who reported their own birth weight (fetal variants), and up to 181,883 female UK Biobank participants who reported the birth weight of their first child (maternal variants). The identified genes highlight key roles for adipose tissue regulation and fetoplacental angiogenesis, in addition to the role of insulin-like growth factor bioavailability and signalling, in regulating human birth weight. 82 83 84 85 86 87 88 89 90

Results 91

We identified 8 genes in which rare (MAF<0.1%) deleterious LoF fetal variants, defined as either high-confidence protein truncating variants, or missense variants with a CADD score 92 93

>=25, were associated with birth weight at exome-wide significance (BOLT-LMM *P*<1.64×10-6): *ACVR1C*, *IGF1R, INHBE*, *NOS3, NRK, NYNRIN, PAPPA2*, *PPARG* (**Figure 1, Supplementary Figures 1-3, Supplementary Table 1**). In the analysis of maternal variants and offspring birth weight, 3 genes showed associations at exome-wide significance (BOLT-LMM P <1.58×10⁻⁶). These included 2 genes also identified in the fetal analysis (*IGF1R*, *NOS3*) and additionally *ADAMTS8* (**Figure 1, Supplementary Figures 4-5, Supplementary Table 1**). We also confirmed all of these significant associations by conducting independent analyses using REGENIE (see Methods) and we did not observe any method-related biases (**Supplementary Figures 1, Supplementary Table 1**). 94 95 96 97 98 99 100 101 102

Figure 1 | Exome-wide rare (MAF<0.1%) fetal or maternal variant gene burden associations with birth weight. (a) Miami plot showing gene burden test results from BOLT-LMM for birth weight, with the fetal exome-wide analysis (up to n=234,675) on the top panel and the maternal exome-wide analysis (up to n=181,883) on the bottom panel. Gene associations passing exome-wide significance, at *P*<1.64×10-6 in the fetal analysis and *P*<1.58×10⁻⁶ in the maternal analysis, are labelled. The two variant collapsing masks are indicated by point shapes. (b) QQ plots for exome-wide gene burden associations. Results for the exome-wide significant genes are included in Supplementary Table 1. 103 104 105 106 107 108 109 110

111

120

Since maternal and fetal genotypes are correlated (r=0.5), we explored whether the observed associations represented fetal effects, maternal effects, or both. To do this, we used a weighted linear model (WLM) to approximately condition the fetal effect on the maternal genotype, and vice versa. Five out of nine associations (*ACVR1C*, *INHBE*, *NRK*, *NYNRIN*, *PPARG*) showed evidence of only fetal-genotype effects. *IGF1R, PAPPA2,* and *NOS3* were classified as both fetal- and maternal-acting, with rare variants in all three genes associating with a lower birth weight in both cases. *ADAMTS8* was the only gene classified as only maternal-acting (**Figure 2a**, **Supplementary Table 2**). 112 113 114 115 116 117 118 119

For fetal genes associated with birth weight, we explored whether they might act in a sex-specific manner. We found a nominally stronger effect for fetal *PPARG* variants on birth weight in females (beta_{Female}=-1.710 [0.340] SDs) than in males (beta_{Male}=-0.177 [0.592] SDs, *p*het=2.46×10-02), albeit only 3 male carriers were identified (**Figure 2b**, **Supplementary Table 3**). 121 122 123 124 125

126

Figure 2 | **Nine genes with rare variant associations with birth weight.** (a) Weighted-linear models (WLMs) approximately conditioned the fetal effect on the maternal genotype, and vice versa. Marker opacity indicates gene burden associations at *P*<0.05. (b) Sexually-dimorphic effects of the associated genes on birthweight. Markers are coloured yellow or red to indicate female- or male-only models. Marker opacity indicates associations with sexual dimorphism (P<0.05). Units for effect estimates and accompanying 95% CIs are SDs in both panels. Relevant data are included in Supplementary Tables 2 and 3, accordingly. 127 128 129 130 131 132 133 134

Confirmation of exome associations 135

We aimed to replicate our associations in independent data on up to 45,622 Icelandic genomes. Despite the substantially smaller sample size than our discovery sample, we observed supportive evidence for the same type of rare LoF exome variants on birth weight 136 137 138

for the majority of our associations (10/11 showed directional consistency; Sign test *P*=0.01), with three genes associated at *P*<0.05; *INHBE*, *NRK* and *PAPPA2* (**Supplementary Figure** 139 140

6, **Supplementary Table 4**). 141

142

To identify whether any of the birth weight genes identified in our exome analyses are also supported by common variant associations, we examined the latest maternal and fetal GWAS summary statistics for birth weight 6 and looked for GWAS signals within 500kb of our identified genes. We observed fetal GWAS signals proximal to *ACVR1C*, *IGF1R*, and *PAPPA2*, and there was also a maternal GWAS signal proximal to *NOS3* (**Supplementary Figure 7**). In all cases the lead associated variants were located within these genes (**Supplementary Table 5**) and proximity has been shown to be a good predictor of the causal gene at a GWAS locus^{[8,9](https://www.zotero.org/google-docs/?R0hw69)}. The lead SNPs at the *IGF1R* and *NOS3* loci were also eQTLs for these genes, with directions of effect concordant with the exome associations, i.e. the alleles associated with lower expression (LoF-like) were also associated with lower birth weight^{[10](https://www.zotero.org/google-docs/?z3txzM)}. Of these four GWAS signals, *IGF1R*, *ACVR1C*, and *PAPPA2* were classified as having fetal only effects by Juliusdottir *et al.*^{[6](https://www.zotero.org/google-docs/?Btcyez)}. The SNP near *NOS3* was not classified by Juliusdottir *et al.*⁶, but the *NOS3* lead SNP was classified by Warrington *et al*. [5](https://www.zotero.org/google-docs/?iZsFfY) as having only maternal effects. We did not observe attenuation of the rare variant associations with birth weight when conditioning on the proximal GWAS sentinel SNPs (**Supplementary Table 6**). Hence, these common variant associations provide independent support for these genes in the regulation of birth weight. 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159

160

To assess evidence for additional candidate genes influencing birth weight at GWAS loci, which did not pass our stringent exome-wide significance thresholds, we looked at all genes within 300 kb of a reported GWAS locus and applied a Benjamini-Hochberg correction for multiple testing. The results are shown in **Supplementary Table 7**. In the fetal variant analysis we identified a further eight candidate genes (*CDK6, HGS, PAPPA, PHF19, PLAG1, PLCE1, PTEN* and *SKP2*), and in the maternal variant analysis we identified one additional candidate gene (*LMNA*). At six of these genes (*CDK6, PAPPA, PHF19, PLAG1*, *PLCE1* and *SKP2*) a GWAS lead SNP was located within the same gene, while the lead SNP within *PLCE1* was also a missense variant, further adding to the evidence that non-synonymous coding variation in these genes affects birth weight. 161 162 163 164 165 166 167 168 169 170

171

Finally, we explored whether the biology implicated by the exome-associated genes was consistent with that from GWAS studies. To do this, we performed a pathway enrichment analysis, using genes proximal to the GWAS signals from Juliusdottir *et al.*[6](https://www.zotero.org/google-docs/?2xj7tF) . We saw enrichment for 185 GO pathways in the fetal GWAS of birth weight and 41 pathways in the maternal GWAS, with 21 pathways being enriched in both GWAS (fetal and maternal, **Supplementary Table 8**). In line with biology implicated by our exome associations, we observed significant enrichment for genes in multiple pathways implicated in insulin and growth factor response across both fetal and maternal GWAS genes and "circulatory system development" for fetal GWAS genes, among others. 172 173 174 175 176 177 178 179 180

Gene burden associations with related traits 181

To understand the wider phenotypic impacts of birth weight-associated rare genomic variation, we performed phenotypic association lookups in birthweight-related traits using data from the UK Biobank (see **Methods**). 182 183 184

185

We observed associations for rare LoF variants in *IGF1R* and *PAPPA2*, both of which are known regulators of insulin-like growth factor (IGF) regulation and bioactivity ¹¹⁻¹⁵, with adult circulating IGF-1 levels, adult height and childhood height and body size (**Supplementary Table 9**). The *INHBE, NRK*, *NOS3* and *NYNRIN* genes were also associated with adult height. In all of these genes, apart from *INHBE*, carrying a rare LoF variant was associated with directionally concordant effects on birth weight and adult height, i.e. higher birth weight and higher adult height or *vice versa*. 186 187 188 189 190 191 192

193

Furthermore, we observed associations between variants in *ADAMTS8* and *NOS3* and adult blood pressure (**Supplementary Table 9**). For both of these genes, rare LoF variants were associated with lower birth weight and higher blood pressure. 194 195 196

197

Finally, several of the birth weight associated genes were also associated with measures of adiposity in adulthood, including waist-hip ratio (WHR) adjusted for BMI, and body fat percentage for rare LoF variants in *ACVR1C*, *INHBE* and *PPARG* (accordingly, **Supplementary Table 9**). These are further explored below. 198 199 200 201

ACVR1C, *INHBE* and favourable adiposity 202

ACVR1C (birth weight: beta_{fetal}=0.330 SDs, p=1.4×10⁻⁶, N=200 carriers, Figure 3a) encodes a type I receptor for the TGF-beta family of signalling molecules. It is predominantly expressed in adipose tissue^{[10](https://www.zotero.org/google-docs/?ycDfEI)} and its primary function in metabolic regulation is to limit catabolic activities and preserve energy^{[16](https://www.zotero.org/google-docs/?iFwgMI)}. Low-frequency heterozygous mutations in humans have been linked to a favourable metabolic profile including lower WHR adjusted for BMI and protection against T2D^{[17,18](https://www.zotero.org/google-docs/?q63Xs3)}. INHBE (beta_{fetal}=0.218 SDs, p=3.5×10⁻⁹, N=687 carriers, Figure **3b**) encodes the inhibin subunit beta E of activin E, a growth factor belonging to the TGF-beta family. While this gene is predominantly expressed in the liver^{[10](https://www.zotero.org/google-docs/?Mdw8zF)}, it does not appear to be necessary for normal liver function^{[19](https://www.zotero.org/google-docs/?qAqURJ)}, but rather acts as a negative regulator of energy storage in peripheral adipose tissue. Similarly to *ACVR1C*, a candidate receptor, heterozygous LoF carriers exhibit lower WHR adjusted for BMI and a favourable body fat distribution and metabolic profile $20,21$. However, recent mouse studies $22,23$ showed that complete ablation of INHBE or ACVR1C leads to uncontrolled and pathological levels of lipolysis (see Discussion). We found that rare LoF variants in *ACVR1C* and *INHBE* are associated with increased birth weight and decreased WHR, indicative of a metabolically favourable adiposity pattern in adulthood (**Supplementary Table 9**). 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218

219

Two genetics studies [20,21](https://www.zotero.org/google-docs/?5mqzR5) showed that the association between rare LoF variants in *INHBE* and WHR is primarily due to a splice acceptor variant (12:57456093:G:C) that substantially reduces the expression of the gene, attributable to either a change in secretion and/or protein 220 221 222

stability. They also reported that the favourable adiposity effect of this gene is almost entirely attenuated in the absence of this variant (gene-burden *p*=2.01×10−8 with splice variant, p=0.34 without^{[21](https://www.zotero.org/google-docs/?TjZyHf)}, which we also observe for WHR in our data (Supplementary Table 10). However, while this variant is also strongly associated with higher birth weight (p=5.4×10⁻⁶, **Figure 3b**), our observed birth weight association with *INHBE* does not fully attenuate in the absence of this variant (gene-burden $p=4.6\times10^{-9}$ with splice variant, $p=6.3\times10^{-5}$ without, **Supplementary Table 10**). 223 224 225 226 227 228 229

231

MISSENSE + PTV variants in INHBE with MAF<0.1% - Fetal analysis

Figure 3 | Rare variant associations at *INHBE* **and** *ACVR1C* **with fetal birth weight in the UK Biobank.** Fetal variant-level associations between *ACVR1C* (a), *INHBE* (b) and birth weight. Included variants had a minor allele frequency (MAF) <0.1% and were annotated to be damaging variants defined as high-confidence protein truncating variants (PTV) or missense variants with a CADD score ≥25. Each variant is presented as an individual line extending to its association p -value $(-\log_{10})$ in the direction indicating the direction of effect on birth weight in variant carriers. Dashed lines indicate PTVs and solid lines indicate missense variants. The point size indicates the number of carriers of each variant (i.e. the allele count). 232 233 234 235 236 237 238 239

240

PPARG in birth weight, adipogenesis, and placental formation 241

PPARG (birth weight: beta_{fetal}=-1.416 SDs, p=1.2×10⁻⁶, N=11 carriers, Figure 4b) encodes the peroxisome proliferator-activated receptor PPAR-gamma, which acts as a master regulator of adipogenesis. Heterozygous LoF variants in humans have been linked to familial partial lipodystrophy (FPLD) characterised by loss of subcutaneous fat from the extremities and metabolic abnormalities such as insulin resistance and hypertriglyceridemia $24-27$. Individuals with FPLD due to inherited heterozygous variants have also been shown to have low birthweight for their gestational age, when in the absence of maternal diabetes, hypertension or hypertriglyceridemia (e.g. when the PPARG variants are paternally inherited)^{[28](https://www.zotero.org/google-docs/?z5BmxG)}. In addition to being highly expressed in adipocytes, *PPARG* is also highly expressed in trophoblasts in both rodent and human placentas^{[29](https://www.zotero.org/google-docs/?9Lkf7t)} where it appears to play an important role in placental formation and angiogenesis by regulating the expression of proangiogenic factors such as proliferin (Prl2c2) and vascular endothelial growth factor (VEGF)^{[30](https://www.zotero.org/google-docs/?CudmoA)}. Its depletion results in embryonic lethality in mice due to placental dysfunction ^{[31,32](https://www.zotero.org/google-docs/?N52bq4)}, while PPARγ agonist activity was reduced in the blood and placentas of patients with severe preeclampsia, compared to those with normal pregnancy 33 33 33 . 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256

257

To distinguish if our observed birth weight association could be primarily due to PPARG's function in fetal insulin resistance or placental function, we characterised rare variants in PPARG using Missense InTerpretation by Experimental Response (MITER) score data^{[34](https://www.zotero.org/google-docs/?rjtuar)}, as the gold-standard indicator of lipodystrophy-causing *PPARG* missense variants. Although MITER scores are not available for PTV variants, for which we observed the strongest birth weight association, we note that 8 out of our included 9 PTV variants are classified as pathogenic based on ACGS^{[35](https://www.zotero.org/google-docs/?tYtLbH)}. Missense variants with a lipodystrophy-level MITER score (≤-2) were collectively associated with a decrease in adult body fat percentage of similar magnitude to other prediction-based missense variant collapsing masks (p=9.70×10⁻⁵, Figure **4a**, **Supplementary Table 11**). We found only weak evidence of an association between the MITER score variants and birth weight (*p*=0.06), although the effect estimate on birth weight was not significantly different from the other missense masks (**Figure 4a**, **Supplementary Table 11**). There was also no discernible correlation pattern between *PPARG* variant effect estimates on birth weight, body fat percentage and their corresponding MITER scores (Pearson correlations were, R_{BW-MITER}=0.026, R_{BF%-MITER}=0.187, R_{BF%-BW}=0.101, Figure 4c). Taken together, our results suggest that the effects of rare *PPARG* PTVs on birth weight could be due to altered placentation, as well as the established role in adipogenesis. 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274

- 275
- 276

Figure 4 | Associations with rare LoF variants in *PPARG***.** (a) Different (fetal) variant collapsing masks and their associations with birth weight (top) and adult body fat percentage (bottom). (b) The genomic location and associations with birth weight for all qualifying fetal high confidence PTVs within *PPARG*, in the discovery analysis. (c) Scatterplot of association P-values for birth weight (fetal variants) and body fat percentage, for all rare missense variants in PPARG annotated with a MITER score and found in the UK Biobank population. Marker colour indicates the variants MITER score, with scores ≤-2 indicating lipodystrophy-level MITER scores. Relevant data is included in **Supplementary Table 11**. 278 279 280 281 282 283 284 285

286

As with *PPARG,* the *ADAMTS8*, *NRK* and *NOS3* genes have also been implicated in placental function. Specifically, *ADAMTS8* shows strong placental expression in the early stages of gestation and has been implicated in endometrium decidualization and trophoblast invasion [36–39](https://www.zotero.org/google-docs/?bIAtyD) . *NRK* encodes a serine/threonine kinase of the germinal centre kinase family and is expressed in skeletal muscle during development as well as the placenta, specifically the spongiotrophoblast layer, a fetus-derived region of the placenta ⁴⁰⁻⁴². Nrk-deficient mouse fetuses display enlarged placentas, a likely result of enhanced trophoblast proliferation due to upregulation of AKT phosphorylation^{[43](https://www.zotero.org/google-docs/?rCHyG2)}, as well as a higher birth weight and delayed delivery through yet unknown mechanisms^{[42](https://www.zotero.org/google-docs/?CqANZZ)}. Finally, common variants in *NOS3* have been previously associated with the risk of developing preeclampsia^{[44](https://www.zotero.org/google-docs/?A14Gvb)}, although no association was found at this locus in a large-scale preeclampsia GWAS^{[45](https://www.zotero.org/google-docs/?qUHe9q)}. 287 288 289 290 291 292 293 294 295 296 297

Comparison of burden test results with birth weight effects of pathogenic *GCK* variants 298 299

To investigate the sensitivity of our ExWAS approach to detect known rare variant effects on birth weight, we focused on the *GCK* gene. In the UK, pathogenic variants in *GCK* are the second most common cause of monogenic diabetes, and have established effects on fetal growth [4,46](https://www.zotero.org/google-docs/?vx5wke) . Mothers with pathogenic *GCK* variants have a stably raised fasting glucose level, which results in greater glucose availability to the fetus, and increased birth weight due to fetal insulin secretion, which is raised in response to higher maternal and consequently fetal glucose. Conversely, fetal growth is reduced in babies who carry pathogenic *GCK* variants due to their reduced insulin secretion. These birth weight effects are masked if both mother and fetus carry the same mutation^{[4](https://www.zotero.org/google-docs/?5FE3va)}. We annotated and combined pathogenic variants in GCK using clinical guidelines 35 and observed evidence of both fetal and maternal genetic associations with birth weight in the expected directions (beta_{fetal}=-0.311 SDs, p=0.002, N=86 carriers; beta_{maternal}=0.430 SDs, p=0.001, N=53 carriers; **Supplementary Figure 8; Supplementary Table 12**). In comparison, our gene burden associations with rare predicted LoF variants in *GCK* were more modest but in the expected directions (**Supplementary Figure 8; Supplementary Table 12**). We found 63 of the known pathogenic *GCK* variants present in the UK Biobank WES dataset. Out of 16 variants in the PTV mask, 14 were annotated as pathogenic and of 55 variants in the Missense + PTV mask, 33 were annotated as pathogenic. The remaining pathogenic variants were annotated as non-deleterious and were not included in the masks. 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318

Discussion 319

In this study, we used whole exome sequencing data from the UK Biobank cohort to understand the influence of rare genetic variants on human birth weight. We aimed to identify genes harbouring rare variants that impact birth weight when carried by either the fetus or the mother. We identified a total of 8 genes with rare fetal LoF variant effects on birth weight, two of which, *IGF1R* and *NOS3* showed some evidence of maternal effects. We identified one additional maternal effect gene, *ADAMTS8*. Findings were largely consistent in an independent cohort of Icelandic genomes, and four of the identified genes harboured independent GWAS lead SNPs in the largest and most recent birth weight GWAS meta-analysis, providing additional confirmation that the genes identified in this study are involved in birth weight regulation. 320 321 322 323 324 325 326 327 328 329

330

Among the genes associated with birth weight, several have well-established links with fetal growth. *IGF1R* and *PAPPA2* encode key components of IGF bioavailability and signalling. IGF1R is a transmembrane receptor tyrosine kinase activated by IGF1 (and also IGF2 and insulin), which mediates anabolic effects. Rare human homozygous, heterozygous or compound heterozygous mutations in *IGF1R* cause intrauterine growth restriction, reduced postnatal growth, short stature and microcephaly^{[47](https://www.zotero.org/google-docs/?gda3p4)}. PAPPA2 encodes a metalloproteinase that regulates the bioavailability of IGFs. Rare homozygous mutations in *PAPPA2* are reported to cause severe short stature but with unclear effects on birth weight (reduced in 4 331 332 333 334 335 336 337 338

of 6 affected children)^{[48](https://www.zotero.org/google-docs/?ZSZ49N)}, while the protein originates primarily from trophoblasts in the early placenta[49,50](https://www.zotero.org/google-docs/?Thlir2) . Our findings demonstrate that rare, damaging variants in *IGF1R* and *PAPPA2* contribute to population variation in birth weight, as well as in childhood and adult height. 339 340 341

342

Consistent with the fetal insulin hypothesis 51 , the association between the rare, damaging fetal variants in *IGF1R* and greater type 2 diabetes risk provides a potential mechanistic insight into the well-documented link between this later-life disease and lower birth weight. *IGF1R* is central to the development of several key tissues for glucose metabolism, including pancreatic islets, adipose tissue and skeletal muscle^{[52](https://www.zotero.org/google-docs/?2dMpPj)}, and in addition, loss of IGF1R function may lead to compensatory increases in growth hormone levels, which are associated with insulin resistance^{[53](https://www.zotero.org/google-docs/?uKo1W8)}. The mechanism underlying the association we observed between maternal rare, damaging *IGF1R* variants and lower offspring birth weight after adjustment for fetal genotype is, however, less clear because we would expect such variants to increase birth weight if they result in higher maternal insulin resistance with concomitant higher glucose availability. However, there are some reported cases of heterozygous IGF1R mutations leading to hypoglycemia^{[54](https://www.zotero.org/google-docs/?TQmtXr)}. We recommend that this result is confirmed in well-powered samples of mother-child pairs before potential mechanisms are investigated. 343 344 345 346 347 348 349 350 351 352 353 354 355

PPARG, *INHBE*, and *ACVR1C* displayed fetal effects on birthweight and are involved in adipose tissue differentiation and regulation. Recent genetics studies implicated rare LoF variants in *INHBE* in adult favourable adiposity traits, i.e. lower WHR adjusted for BMI ^{[20,21](https://www.zotero.org/google-docs/?UCE4Bs)}. They also highlighted a splice variant (12:57456093:G:C) which affects either protein secretion or stability, as underpinning the favourable adiposity association with this gene. We found that the birth weight association with *INHBE* largely remains, even in the absence of this splice variant. This could indicate that some variants within *INHBE* may exert a role in early (*in utero*) adipogenesis, while others may do so throughout the life course, but further studies need to confirm this hypothesis. 357 358 359 360 361 362 363 364 365

366

356

Our identification of rare LoF variants in two genes, *ACVR1C* and *INHBE*, that have fetal associations with higher birth weight and also a more metabolically favourable body fat distribution in adulthood is in line with recent findings that common genetic variants in the fetus, which predispose to higher metabolically favourable adiposity in adulthood, are also associated with higher birth weight. Variants with greater effects on adiposity have greater effects on birth weight^{[55](https://www.zotero.org/google-docs/?eY5aRn)} and we therefore hypothesise that the birth weight effects of *ACVR1C* and *INHBE* are due primarily to fetal fat accretion rather than effects on lean mass. A fetal genetic predisposition to greater birth weight and later favourable body fat distribution may underlie epidemiological associations between greater skinfold thickness at birth and favourable metabolic outcomes in early childhood, especially when controlling for exposure to maternal glucose levels *in utero*^{[56](https://www.zotero.org/google-docs/?y08I4K)}. Further studies should assess the contributions of rare variation in *ACVR1C* and *INHBE* to the fat and lean mass components of birth weight. 367 368 369 370 371 372 373 374 375 376 377 378

379

More generally, the effects of loss of INHBE on Alk7 (ACVR1C) signalling on metabolic health appear to be complex and dose-dependent. Humans haploinsufficient for either of these genes have a healthy metabolic profile and reduced risk of cardiometabolic disease 380 381 382

accompanied by a favourable distribution of body fat. However, it has been shown that the total absence of either INHBE or ACVR1C from conception results in uncontrolled adipocyte lipolysis, ectopic fat distribution and insulin resistance, at least in mice $22,23$. This discrepancy may be explained by the fact that Alk7 signalling in adipose cells suppresses the expression of both PPARγ and key molecular elements of the lipolytic machinery. We suggest that at modest levels of INHBE/Alk7 deficiency, such as occurs when only one functional allele is present, the effect on PPARγ is dominant and carriers of such mutations develop more subcutaneous adipocytes as a result of the enhanced PPARG tone during development. Ultimately, this is metabolically beneficial as it will tend to protect the individual from any effects of any caloric overload in postnatal life. However, in the total absence of INHBE/Alk7 the effect on lipolysis becomes dominant with consequent build-up of ectopic fat and insulin resistance. While it is not entirely clear why subcutaneous, rather than visceral adipocytes would be favoured by PPARγ activity, it is worthy of note that the administration of drugs activating PPARγ preferentially promotes subcutaneous fat deposition^{[57](https://www.zotero.org/google-docs/?fqbZFw)}. 383 384 385 386 387 388 389 390 391 392 393 394 395 396

397

Heterozygous LoF in *PPARG* has previously been linked to familial partial lipodystrophy, characterised by the loss of subcutaneous fat from the extremities and metabolic abnormalities such as insulin resistance and hypertriglyceridemia [24–27](https://www.zotero.org/google-docs/?srnmc4) . However, *PPARG* has also been linked to placental development and angiogenesis^{[30](https://www.zotero.org/google-docs/?AcqHja)}. Here, we saw a poor correlation between the variants' lipodystrophy-causing potential and effect on birth weight, suggesting the birth weight effect could be driven by another mechanism. Given the role of *PPARG* in placental development, it is possible that *PPARG* LoF variants act via the placenta to exert an effect on birth weight. Our results are consistent with recent observations of a high rate of small-for-gestational-age birth weights in patients who had familial partial lipodystrophy due to inherited *PPARG* mutations and who were not exposed to maternal diabetes in utero^{[28](https://www.zotero.org/google-docs/?IjXB1d)}. PPARG mutation carriers were also more likely to be born preterm, regardless of maternal diabetes status, which further supports the role of fetal *PPARG* in placental development. Data on gestational duration was not available for the UK Biobank participants, and it is possible that shorter gestation in rare *PPARG* variant carriers contributed to the associations we observed with birth weight. We note that the common fetal variant rs1801282 in PPARG, which is associated with type 2 diabetes risk in adulthood^{[58](https://www.zotero.org/google-docs/?NbtNbs)} via a fat distribution-mediated form of insulin resistance^{[59](https://www.zotero.org/google-docs/?wvshPX)}, is weakly associated with lower birth weight (p=0.0259*)* [5](https://www.zotero.org/google-docs/?dvAA4z) and was not associated with gestational duration in a fetal GWAS of gestational duration in 84,689 individuals ($p=0.487$)^{[60](https://www.zotero.org/google-docs/?cR5amg)}. Our observed associations between birthweight and *ADAMTS8*, *NRK* and *NOS3* are also likely driven by placental mechanisms, given the known roles of these genes ^{[36–44](https://www.zotero.org/google-docs/?Ndah7X)}. The potential mechanism underlying the association between birth weight and our other identified gene, *NYNRIN*, requires further study. 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419

420

Our study has several strengths, including a large discovery sample, an independent replication sample, support from common variant associations proximal to five of the genes, and approximate adjustment for correlation between maternal and fetal genotype. However, there are limitations. The sample size available for replication was limited, and although we observed strong evidence for consistent effect estimates, we recommend confirmation in larger datasets as they become available, along with proper conditional analyses in 421 422 423 424 425 426

sufficiently-powered samples of mother-child pairs. The approximate adjustment for the correlation between maternal and fetal genotype used here is based on the strong assumption that all variants with a given annotation have equal effects on birth weight^{[5](https://www.zotero.org/google-docs/?8JTJnH)}, which may not be the case. We also acknowledge the limited diversity of our samples. Studies of rare variants in well-powered samples of diverse ancestries are a priority for future research. While our study was underpowered to detect very rare pathogenic variants that have known birth weight effects^{[2](https://www.zotero.org/google-docs/?qcKPnx)}, our sensitivity analysis of GCK showed that the known maternal and fetal associations were detectable by our method, despite the inevitable lower sensitivity and specificity of the exome-wide approach, and despite the lack of adjustment for opposing effects of maternal and fetal genotypes. 427 428 429 430 431 432 433 434 435 436

437

Overall, this study advances our understanding of the fetal and maternal genetic underpinnings of birth weight, providing strong evidence for causal genes and insights into biological pathways which are important targets for future research aiming to understand fetal growth and its links with long-term health. 438 439 440 441

Acknowledgements 442

This research has been conducted using the UK Biobank Resource under Application Numbers 9905 and 7036. UK Biobank data has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB). 443 444 445

Use of the Icelandic data was approved by the National Bioethics Committee (VSN-15-169). All genotyped participants signed a written informed consent allowing the use of their samples and data in projects at deCODE genetics approved by the NBC. Data were anonymized and encrypted by a third-party system, approved and monitored by the Icelandic Data Protection Authority^{[61](https://www.zotero.org/google-docs/?KFU1E7)}. 446 447 448 449 450

B.E.M.L., R.N.B. and R.M.F. were supported by a Wellcome Senior Research Fellowship (WT220390). This research was funded in part by the Wellcome Trust (WT220390). R.M.F. is also supported by a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R01HD101669. K.A.K., L.R.K., E.J.G., Y.Z., F.R.D., K.K.O. and J.R.B.P. are supported by the Medical Research Council (MC_UU_00006/2). This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre and the NIHR Cambridge Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. 451 452 453 454 455 456 457 458 459 460 461

462

Author contributions 463

K.A.K., B.E.M.L., L.R.K., K.K.O., R.N.B., J.R.B.P., and R.M.F. analysed and interpreted the original data and wrote the manuscript. V.S., V.T., T.O., G.T., and K.S. contributed the Icelandic replication data. L.S., K.A.P., G.H., E.J.G., A.R.W., Y.Z., F.R.D., S.E.O., A.T.H., and S.O. contributed to data analysis and/or interpretation. All authors revised, critically reviewed and approved the manuscript. 464 465 466 467 468

469

Competing interests 470

J.R.B.P. and E.J.G. are employees/shareholders of Insmed. J.R.B.P. also receives research funding from GSK. Y.Z. is a UK University worker at GSK. S.O. has undertaken remunerated consultancy work for Pfizer, Third Rock Ventures, AstraZeneca, NorthSea Therapeutics and Courage Therapeutics. V.S., V.T., T.O., G.T., and K.S. are employees of deCODE genetics, a subsidiary of Amgen. 471 472 473 474 475

476

Code availability 477

Code for WES data processing and association testing is available on GitHub [\(https://github.com/mrcepid-rap/mrcepid-runassociationtesting\)](https://github.com/mrcepid-rap/mrcepid-runassociationtesting). No custom code was developed for this study. 478 479 480

Data availability 481

- UK Biobank data are available on application via 482
- <https://www.ukbiobank.ac.uk/enable-your-research/register>. 483

Materials and methods 484

Exome wide association analyses in the UK Biobank 485

Analyses of the UK Biobank data were performed on the UK Biobank Research Analysis Platform (RAP; <https://ukbiobank.dnanexus.com/>). Birth weight was derived in the 453,505 UK Biobank participants with genetically defined European ancestry, as follows. Own birth weight (fetal genotype analysis) was derived using self-reported data (field 20022), while birth weight of the first child in UK Biobank women (maternal genotype analysis) was taken from hospital records and self-reports (fields 41284 and 2744). Data from each field were converted to kg (if in another unit) and if both were available, hospital records were preferentially retained for maximum accuracy. For both phenotypes, repeated responses across the assessment centre visits were combined by calculating average values. Individuals from multiple births (field 1777), who reported substantially different values between visits (>1kg difference), or extreme birth weight values (<1 or ≥7kg) were excluded from downstream analyses. After these exclusions, fetal birth weight data was available for 252,329 individuals (234,675 with exome and covariate data) and maternal birth weight data was available for the first child of 195,653 women (181,883 with exome and covariate data). 486 487 488 489 490 491 492 493 494 495 496 497 498 500

499

We conducted gene burden tests for both fetal and maternal birth weight, by combining effects of all rare (MAF <0.1%) variants with predicted deleterious functional consequences across all protein-coding genes, as described in detail in Gardner *et al*. [53](https://www.zotero.org/google-docs/?w0BwP6) . Briefly, we queried population-level VCF files with data for 454,787 individuals provided from the UK Biobank study. Using bcftools^{[62](https://www.zotero.org/google-docs/?suaOPO)} multi-allelic variants were split and left-normalised, and all variants filtered using a missingness based approach. SNV genotypes with depth <7 and genotype quality <20 or InDel genotypes with a depth <10 and genotype quality <20 were set to missing. We also tested for an expected reference and alternate allele balance of 50% for heterozygous SNVs using a binomial test; SNV genotypes with a binomial test p. value ≤1×10-3 were set to missing. Following genotype filtering, variants with >50% missing genotypes were excluded from further analysis. Variants were then annotated with the ENSEMBL Variant Effect Predictor (VEP 63 63 63 , v104) with the 'everything' flag and the LOFTEE plugin^{[64](https://www.zotero.org/google-docs/?ZE5iBs)}. For each variant we prioritised a single MANE (v0.97) or VEP canonical ENSEMBL transcript and most damaging consequence as defined by VEP defaults. For the purposes of defining Protein Truncating Variants (PTVs), we grouped high-confidence (as defined by LOFTEE) stop gained, splice donor/acceptor, and frameshift consequences. To define 'high-confidence' PTVs, we used the LOFTEE algorithm 64 64 64 . All variants were subsequently annotated using CADD ($v1.6$, 65). We then assessed the association between rare variant burden and birth weight, using BOLT-LMM ($v2.3.5$, 66 66 66) and a set of dummy genotypes representing per-gene carrier status, under two overlapping variant collapsing masks; i) 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520

high-confidence protein truncating variants (denoted PTV) and ii) High-confidence PTVs plus missense variants with CADD scores ≥25 (denoted Missense + PTV). All analyses were controlled for age, age², the first ten genetic ancestry principal components as calculated in Bycroft et al.^{[67](https://www.zotero.org/google-docs/?rfIA3T)}, WES batch, and sex when running sex-combined analyses. We excluded genes with <10 carriers of variants per mask. 521 522 523 524 525

526

This led to testing 16,735 genes with qualifying Missense + PTV variants and 13,684 with PTVs for fetal birth weight, and 17,745 with Missense + PTV variants and 13,968 with PTVs for maternal birth weight. The exome-wide significance thresholds were thus set to *p*=1.64×10-6 (0.05/(16735+13684)) for fetal birth weight and *p*=1.58×10-6 (0.05/(17745+13968)) for maternal birth weight. 527 528 529 530 531

Confirmatory gene burden analyses 532

To replicate the findings from the above analysis and account for potential bias arising from only using one discovery approach, a second team independently derived the birth weight phenotypes for the maternal and fetal genetic analyses and conducted additional burden association analyses, specifically for the significantly associated birth weight genes. 533 534 535 536

Own birth weight (fetal genotype analysis) was derived using self-reported data (field 20022), excluding individuals who were part of a multiple birth (field 1777). Offspring birth weight (maternal genotype analysis) was derived from self reported weight of first child (field 2744). Where individuals reported their birth weight at more than one assessment centre visit, reported birth weights were averaged unless the weights differed by ≥1 kg, in which case they were excluded. Own and offspring birth weight were available in 269,921 (232,876 with exome and covariate data) and 216,798 (152,585 with exome and covariate data) individuals respectively. 537 538 539 540 541 542 543 544

545

Multiallelic variants were similarly split and left-normalised. Variants flagged for exclusion by UK Biobank were removed, and remaining variants were annotated with their functional consequence in canonical transcripts using the Ensembl Variant Effect Predictor and the CADD and LOFTEE plugins ([https://github.com/konradjk/loftee\)](https://github.com/konradjk/loftee). Association testing was performed using REGENIE (v3.1.3, 68 68 68), and variants were grouped according to two collapsing masks; i) loss of function variants defined by LOFTEE as high confidence (denoted PTV) and ii) LoF plus missense SNVs or inframe insertions or deletions with CADD scores ≥25 (denoted Missense + PTV). All analyses were controlled for maternal age at first birth (field 3872) or year of birth, sex (for fetal birth weight), assessment centre, WES sequencing batch, and the first ten principal components. 546 547 548 549 550 551 552 553 554 555

556

Exome-wide significantly associated genes from the above BOLT-LMM analysis were queried in the REGENIE results. 557 558

Follow-up analyses of identified genes 559

To distinguish between fetal genotyping-acting ('fetal-acting') and maternal genotype-acting ('maternal-acting') effects at each birth weight-associated gene, we applied a weighted linear model (WLM) to the burden test results. WLM estimates associations of fetal genotype conditional on maternal genotype, and vice versa, without the need for data from mother-child pairs. The WLM approach has been described previously^{[5](https://www.zotero.org/google-docs/?Y7f7Gk)}. 560 561 562 563 564

565

To investigate potential sexual dimorphism, we performed sex-stratified burden tests using generalised linear models in the discovery sample and for the most strongly associated mask-gene combination. Sex-stratified effect estimates for each gene were compared using two-sample T-tests. Associations were deemed dimorphic if the *p*-value for the T-test was $< 0.05.$ 566 567 568 569 570

571

Where described, further missense variant collapsing masks and leave-one out analyses were tested using BOLT-LMM or linear models in the same individuals and birth weight outcomes as the discovery analyses. Such masks were defined using a combination of $CADD^{65}$ $CADD^{65}$ $CADD^{65}$ and REVEL 69 69 69 . 572 573 574 575

576

Conditional analyses where the effect of the identified rare exome variant collapsing masks was conditioned on the genotype at common birth weight GWAS signals were also tested using linear models in the same individuals and birth weight outcomes as the discovery analyses. Genotypes at GWAS signals (as identified in 6) were extracted in this discovery sample using plink (v1.90b6.18, 70 70 70). Birthweight outcomes were regressed against the covariates used in discovery analyses and the concurrent effects of exome variant carriage and GWAS signal genotype were tested against the residual birth weight variance. A change in effect estimate of more than 10% was considered to show significant attenuation in the presence of the GWAS variants. 577 578 579 580 581 582 583 584 585

Related trait PheWAS 586

For all identified exome associations to the two birth weight traits, we performed small-scale PheWAS on a few predefined relevant phenotypes. 587 588

589

For BOLT-LMM analyses, phenotypic outcomes were defined as follows. BMI raw values were used from field 21001. Body fat % was extracted using data from field 23099. Data from subsequent visits were used, if missing for a given instance. Comparative height at age 10 was recoded to have individuals who in field 1697 reported being 'Shorter' as 0, 'About average' as 1, and 'Taller' as 2. Individuals who reported 'Do not know' or 'Prefer not to answer' were set to 'NA'. Following variable recoding, this phenotype was run as a continuous trait. Comparative size at age 10 was defined as above using data from field 1687. Systolic and diastolic blood pressure was derived using data from fields 4079 and 4080, accordingly. For each, the average blood pressure at each assessment visit was calculated over the two available measurements and data from subsequent visits were used, if missing for a given instance. Individuals indicating the use of blood pressure medications in 590 591 592 593 594 595 596 597 598 599 600

fields 6153 and 6177 were adjusted for in the association models. Height raw values were used from field 50. IGF-1 levels were derived using data from field 30770, with exclusion of individuals >5 standard deviations from the mean. T2D was derived as described in 53 and using data from fields 4041, 10844, 2443, 6177, 6153, 20002, 20003, 41202, 41204, 40001and 40002. WHR adjusted for BMI; WHR was calculated using data from field 48 and 49. >4 standard deviations from the mean excluded following initial calculation and prior to adjusting with BMI (field 21001). Paired BMI and WHR data from subsequent visits were used, if missing for a given instance. 601 602 603 604 605 606 607 608

609

For REGENIE analyses, phenotypic outcomes are as follows: BMI was taken from the baseline value for field 21001 and residualised on age at assessment (field 21003), genetic sex (field 22001), assessment centre (field 54) and PCs 1-5. Blood pressure measurements were taken from the automated readings for diastolic blood pressure (field 4079) and systolic blood pressure (field 4080). Where two blood pressure readings were available, the average between the two was taken, excluding individuals where the measurements differed by >4.56 SD. Individuals with a blood pressure >4.56 SD away from the mean were excluded. Blood pressure medication was accounted for by adding 10 and 15 mmHg to diastolic and systolic blood pressure, respectively. Height raw values were taken from baseline values for field 50, where people whose height was 100 cm and sitting height (field 20015) was 20 cm, were removed. Raw IGF-1 values were used from field 30770. Size at age 10 was based on a continuous simulation of childhood BMI. The simulation converted the categorical variables 'thinner', 'the same size' or 'plumper' in field 1687 to a continuous distribution based on the number of individuals selecting each category. The full methods for the simulation have previously been reported^{[71](https://www.zotero.org/google-docs/?eUeVkB)}. WHR was calculated using waist circumference (field 48) and hip circumference (field 49). If a follow-up visit was recorded, the WHR was taken from the follow-up data. Otherwise, it was taken from the first recorded WHR measurement. 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626

627

The multiple testing threshold was set at *p*<0.005, after correcting for the above 10 queried phenotypes. 628 629

GWAS associations at identified loci 630

GWAS signals for fetal and maternal birth weight were accessed from Juliusdottir *et al*. [6](https://www.zotero.org/google-docs/?FyzBUs) . These signals were lifted back to GRCh37 annotated with all proximal genes, defined as those within 500kb up- or downstream of the genes start or end sites, using the NCBI RefSeq gene map for GRCh37 (via [http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/\)](http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/). For signals proximal to the exome-associated genes we assessed whether the exome-associated gene was the closest gene to the GWAS signal. These signals were also queried using eQTL data from the GTEx study (V8, 10 10 10) and plotted using LocusZoom^{[72](https://www.zotero.org/google-docs/?TqoLTj)}. 631 632 633 634 635 636 637

638

We performed gene-centric biological pathway enrichment analysis using g:Profiler (via the R client "gprofiler2"[73](https://www.zotero.org/google-docs/?FimEX9) , v0.2.1, accessed on 23/11/2023). Pathway enrichment analyses were performed using the genes calculated to be the closest per signal to the GWAS signals from Juliusdottir *et al.*[6](https://www.zotero.org/google-docs/?BY8Mcu) . Pathways with a Bonferroni corrected *p*-value<0.05 were considered significantly enriched in the birth weight GWAS. 639 640 641 642 643

644

We also examined all genes within 300 kb of the previously published birth weight loci from Juliusdottir et al.^{[6](https://www.zotero.org/google-docs/?VlYNlN)}. For this restricted set of loci previously shown to have common genetic associations with birth weight, we applied a Benjamini-Hochberg procedure to identify genes with evidence of association. 645 646 647 648

Replication of exome associations in deCODE 649

Data preparation 650

The genome of the Icelandic population was characterised by whole-genome sequencing (WGS) of 63,460 Icelanders using Illumina standard TruSeq methodology to a mean depth of 35x (SD 8x) with subsequent long-range phasing^{[74](https://www.zotero.org/google-docs/?fLYtRg)}, and imputing the information into 173,025 individuals chip-genotyped employing multiple Illumina platforms^{[75](https://www.zotero.org/google-docs/?MPX3mE)}. Variant calling was performed using GraphTyper^{[76](https://www.zotero.org/google-docs/?5P4jMD)} (v2.6) and chip data was phased using SHAPEIT4^{[77](https://www.zotero.org/google-docs/?sMlzE9)}. 651 652 653 654 655

We used Variant Effect Predictor (VEP^{[63](https://www.zotero.org/google-docs/?70wEGl)}) to attribute predicted consequences to the variants sequenced in each dataset. We classified as high-impact variants those predicted as start-lost, stop-gain, stop-lost, splice donor, splice acceptor or frameshift, collectively called loss-of-function (LOF) variants. Variants of moderate impact are those classified as missense, splice-region and in-frame-indels. 656 657 658 659 660

Information on birthweight comes from the Icelandic birth register and Primary Health Care Clinics of the Capital area. Individual's fetal birth weight was available in up to 36,578 genotyped and 11,184 WGS participants, while maternal birth weight was available in 45,622 genotyped and 17,177 WGS participants. 661 662 663 664

Gene burden associations 665

We defined different models to group together various types of variant: (i) only LOF variants, filtered with LOFTEE 64 64 64 ; (ii) LOF and MIS (as described on Variant annotation), when predicted deleterious by CADD^{[65](https://www.zotero.org/google-docs/?FnHWNR)} score \geq 25. In all models, we used MAF < 0.1% to select variants for analyses. 666 667 668 669

Quantitative traits were analysed using a linear mixed model implemented in BOLT-LMM^{[66](https://www.zotero.org/google-docs/?xrZIj3)}. To estimate the quality of the sequence variants across the entire set we regressed the alternative allele counts (AD) on the depth (DP) conditioned on the genotypes (GT) reported by GraphTyper^{[78](https://www.zotero.org/google-docs/?ZqCbLf)}. For a well behaving sequence variant, the mean alternative allele count for a homozygous reference genotype should be 0, for a heterozygous genotype it should be DP/2 and for homozygous alternative genotype it should be DP. Under the assumption of no sequencing or genotyping error, the expected value of AD should be DP conditioned on the genotype, in other words an identity line (slope 1 and intercept 0). Deviations from the identity line indicate that the sequence variant is spurious or somatic. We filter variants with slope less than 0.5. Additionally, GraphTyper employs a logistic regression model that assigns each variant a score (AAscore) predicting the probability that it is a true positive. We used only variants that have a AAscore > 0.8. 670 671 672 673 674 675 676 677 678 679 680 681

Analysis of birth weight associations with pathogenic *GCK* mutations 682

We used a similar procedure to that used to define pathogenic variants in GCK in a recent paper^{[79](https://www.zotero.org/google-docs/?QAVRWz)}. We reviewed all heterozygous missense/PTV variants in UK Biobank participants with whole exome sequencing that were observed at minor allele frequency (MAF) <0.001. We included variants in the analysis if missense/PTV variants were classified as pathogenic or likely pathogenic based on ACMG/AMP guidelines by clinical scientists at Exeter Molecular Genetic laboratory as part of routine clinical diagnostic care (i.e. previously seen in the MODY probands)^{[35](https://www.zotero.org/google-docs/?FbBpFK)} and were ultra-rare in the population (maximum allele count of 2 in gnomADv2.1, MAF $\leq 1.4 \times 10^{-5}$). We manually reviewed sequence read data for all the pathogenic variants (missense and PTVs) in Integrative Genomics Viewer (IGV) to remove false-positive variants. We used linear regression to assess the difference in birth weight associated with being a carrier (separate maternal and fetal analyses) and adjusted for genotype, sex, mother's diabetes status, batch, year of birth, centre and principal components in the fetal analysis and genotype, batch, age at first birth, centre and principal components in the maternal birth weight analysis. We then compared the estimated effects and 95% confidence intervals for the pathogenic variants with those obtained from our PTV and PTV+missense masks in the REGENIE analyses. 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698

References 699

- 700
- 1. Barker, D. J. *et al.* Type 2 (non-insulin-dependent) [diabetes mellitus, hypertension and](https://www.zotero.org/google-docs/?GPYbB4) 701
- [hyperlipidaemia \(syndrome X\): relation to reduced fetal growth.](https://www.zotero.org/google-docs/?GPYbB4) *Diabetologia* **36**, 62–67 702
- [\(1993\).](https://www.zotero.org/google-docs/?GPYbB4) 703
- 2. [Hughes, A. E., Hattersley, A. T., Flanagan, S. E. & Freathy, R. M. Two decades since the](https://www.zotero.org/google-docs/?GPYbB4) 704
- [fetal insulin hypothesis: what have we learned from genetics?](https://www.zotero.org/google-docs/?GPYbB4) *Diabetologia* **64**, 717–726 705
- [\(2021\).](https://www.zotero.org/google-docs/?GPYbB4) 706
- 3. Hughes, A. E. *et al.* Monogenic disease analysis [establishes that fetal insulin accounts](https://www.zotero.org/google-docs/?GPYbB4) 707
- [for half of human fetal growth.](https://www.zotero.org/google-docs/?GPYbB4) *J. Clin. Invest.* **133**, e165402 (2023). 708
- 4. Hattersley, A. T. *et al.* Mutations in the glucokinase [gene of the fetus result in reduced](https://www.zotero.org/google-docs/?GPYbB4) 709
- birth weight. *Nat. Genet.* **19**[, 268–270 \(1998\).](https://www.zotero.org/google-docs/?GPYbB4) 710
- 5. Warrington, N. M. *et al.* Maternal and fetal genetic [effects on birth weight and their](https://www.zotero.org/google-docs/?GPYbB4) 711
- [relevance to cardio-metabolic risk factors.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Genet.* **51**, 804–814 (2019). 712
- 6. Juliusdottir, T. *et al.* Distinction between the [effects of parental and fetal genomes on](https://www.zotero.org/google-docs/?GPYbB4) 713
- fetal growth. *Nat. Genet.* **53**[, 1135–1142 \(2021\).](https://www.zotero.org/google-docs/?GPYbB4) 714
- 7. Hughes, A. E. *et al.* Fetal Genotype and Maternal [Glucose Have Independent and](https://www.zotero.org/google-docs/?GPYbB4) [Additive Effects on Birth Weight.](https://www.zotero.org/google-docs/?GPYbB4) *Diabetes* **67**, 1024–1029 (2018). 715 716
- 8. Aragam, K. G. *et al.* [Discovery and systematic characterization](https://www.zotero.org/google-docs/?GPYbB4) of risk variants and 717
- [genes for coronary artery disease in over a million participants.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Genet.* **54**, 1803–1815 718
- [\(2022\).](https://www.zotero.org/google-docs/?GPYbB4) 719
- 9. Mountjoy, E. *et al.* [An open approach to systematically](https://www.zotero.org/google-docs/?GPYbB4) prioritize causal variants and 720
- [genes at all published human GWAS trait-associated loci.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Genet.* **53**, 1527–1533 (2021). 721
- 10. Lonsdale, J. *et al.* [The genotype-tissue expression](https://www.zotero.org/google-docs/?GPYbB4) (GTEx) project. *Nat. Genet.* **45**, 580 722
- [\(2013\).](https://www.zotero.org/google-docs/?GPYbB4) 723
- 11. [Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental phenotype](https://www.zotero.org/google-docs/?GPYbB4) 724

[and the insulin-like growth factors: resource allocation to fetal growth.](https://www.zotero.org/google-docs/?GPYbB4) *J. Physiol.* **595**, 725

[5057–5093 \(2017\).](https://www.zotero.org/google-docs/?GPYbB4) 726

- 12. Conover, C. A. *et al.* [Metalloproteinase pregnancy-associated](https://www.zotero.org/google-docs/?GPYbB4) plasma protein A is a 727
- [critical growth regulatory factor during fetal development.](https://www.zotero.org/google-docs/?GPYbB4) *Dev. Camb. Engl.* **131**, 1187–1194 728
- [\(2004\).](https://www.zotero.org/google-docs/?GPYbB4) 729
- 13. [Bøtkjær, J. A., Noer, P. R., Oxvig, C. & Yding Andersen, C. A common variant of the](https://www.zotero.org/google-docs/?GPYbB4) 730
- [pregnancy-associated plasma protein-A \(PAPPA\) gene encodes a protein with reduced](https://www.zotero.org/google-docs/?GPYbB4) 731
- [proteolytic activity towards IGF-binding proteins.](https://www.zotero.org/google-docs/?GPYbB4) *Sci. Rep.* **9**, 13231 (2019). 732
- 14. [Yan, X., Baxter, R. C. & Firth, S. M. Involvement of pregnancy-associated plasma](https://www.zotero.org/google-docs/?GPYbB4) 733
- [protein-A2 in insulin-like growth factor \(IGF\) binding protein-5 proteolysis during pregnancy: a](https://www.zotero.org/google-docs/?GPYbB4) 734
- [potential mechanism for increasing IGF bioavailability.](https://www.zotero.org/google-docs/?GPYbB4) *J. Clin. Endocrinol. Metab.* **95**, 735
- [1412–1420 \(2010\).](https://www.zotero.org/google-docs/?GPYbB4) 736
- 15. Dauber, A. *et al.* [Mutations in pregnancy-associated](https://www.zotero.org/google-docs/?GPYbB4) plasma protein A2 cause short 737
- [stature due to low IGF-I availability.](https://www.zotero.org/google-docs/?GPYbB4) *EMBO Mol. Med.* **8**, 363–374 (2016). 738
- 16. [Ibáñez, C. F. Regulation of metabolic homeostasis by the TGF-β superfamily receptor](https://www.zotero.org/google-docs/?GPYbB4) 739
- ALK7. *FEBS J.* **289**[, 5776–5797 \(2022\).](https://www.zotero.org/google-docs/?GPYbB4) 740
- 17. Justice, A. E. *et al.* Protein-coding variants [implicate novel genes related to lipid](https://www.zotero.org/google-docs/?GPYbB4) 741
- [homeostasis contributing to body-fat distribution.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Genet.* 1 (2019). 742
- 18. Emdin, C. A. *et al.* DNA Sequence Variation in [ACVR1C Encoding the Activin](https://www.zotero.org/google-docs/?GPYbB4) 743
- [Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2](https://www.zotero.org/google-docs/?GPYbB4) 744
- Diabetes. *Diabetes* **68**[, 226–234 \(2019\).](https://www.zotero.org/google-docs/?GPYbB4) 745
- 19. [Lau, A. L., Kumar, T. R., Nishimori, K., Bonadio, J. & Matzuk, M. M. Activin betaC and](https://www.zotero.org/google-docs/?GPYbB4) 746
- [betaE genes are not essential for mouse liver growth, differentiation, and regeneration.](https://www.zotero.org/google-docs/?GPYbB4) *Mol.* 747
- *Cell. Biol.* **20**[, 6127–6137 \(2000\).](https://www.zotero.org/google-docs/?GPYbB4) 748
- 20. Akbari, P. *et al.* Multiancestry exome sequencing [reveals INHBE mutations associated](https://www.zotero.org/google-docs/?GPYbB4) 749
- [with favorable fat distribution and protection from diabetes.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Commun.* **13**, 4844 (2022). 750

- 21. Deaton, A. M. *et al.* [Rare loss of function variants in the hepatokine gene INHBE protect](https://www.zotero.org/google-docs/?GPYbB4) [from abdominal obesity.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Commun.* **13**, 4319 (2022). 751 752
- 22. Griffin, J. D. *et al.* Hepatic Activin E mediates [liver-adipose inter-organ communication,](https://www.zotero.org/google-docs/?GPYbB4) 753
- [suppressing adipose lipolysis in response to elevated serum fatty acids.](https://www.zotero.org/google-docs/?GPYbB4) *Mol. Metab.* **78**, 754
- [101830 \(2023\).](https://www.zotero.org/google-docs/?GPYbB4) 755
- 23. Adam, R. C. *et al.* Activin E-ACVR1C cross talk [controls energy storage via suppression](https://www.zotero.org/google-docs/?GPYbB4) 756
- [of adipose lipolysis in mice.](https://www.zotero.org/google-docs/?GPYbB4) *Proc. Natl. Acad. Sci. U. S. A.* **120**, e2309967120 (2023). 757
- 24. [Agarwal, A. K. & Garg, A. A novel heterozygous mutation in peroxisome](https://www.zotero.org/google-docs/?GPYbB4) 758
- [proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.](https://www.zotero.org/google-docs/?GPYbB4) *J.* 759
- *[Clin. Endocrinol. Metab.](https://www.zotero.org/google-docs/?GPYbB4)* **87**, 408–411 (2002). 760
- 25. Barroso, I. *et al.* Dominant negative mutations [in human PPARgamma associated with](https://www.zotero.org/google-docs/?GPYbB4) 761
- [severe insulin resistance, diabetes mellitus and hypertension.](https://www.zotero.org/google-docs/?GPYbB4) *Nature* **402**, 880–883 (1999). 762
- 26. [Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a](https://www.zotero.org/google-docs/?GPYbB4) 763
- [transactivation-deficient mutant, in familial partial lipodystrophy.](https://www.zotero.org/google-docs/?GPYbB4) *Diabetes* **51**, 3586–3590 764
- [\(2002\).](https://www.zotero.org/google-docs/?GPYbB4) 765
- 27. Savage, D. B. *et al.* Human metabolic syndrome [resulting from dominant-negative](https://www.zotero.org/google-docs/?GPYbB4) 766
- [mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.](https://www.zotero.org/google-docs/?GPYbB4) 767
- *Diabetes* **52**[, 910–917 \(2003\).](https://www.zotero.org/google-docs/?GPYbB4) 768
- 28. Gosseaume, C. *et al.* Perinatal, metabolic, and [reproductive features in PPARG-related](https://www.zotero.org/google-docs/?GPYbB4) lipodystrophy. *[Eur. J. Endocrinol.](https://www.zotero.org/google-docs/?GPYbB4)* **188**, lvad023 (2023). 769 770
- 29. [Fournier, T., Tsatsaris, V., Handschuh, K. & Evain-Brion, D. PPARs and the placenta.](https://www.zotero.org/google-docs/?GPYbB4) 771
- *Placenta* **28**[, 65–76 \(2007\).](https://www.zotero.org/google-docs/?GPYbB4) 772
- 30. Nadra, K. *et al.* [PPARgamma in placental angiogenesis.](https://www.zotero.org/google-docs/?GPYbB4) *Endocrinology* **151**, 4969–4981 [\(2010\).](https://www.zotero.org/google-docs/?GPYbB4) 773 774
- 31. Barak, Y. *et al.* [PPAR gamma is required for placental,](https://www.zotero.org/google-docs/?GPYbB4) cardiac, and adipose tissue development. *Mol. Cell* **4**[, 585–595 \(1999\).](https://www.zotero.org/google-docs/?GPYbB4) 775 776

- 32. Kubota, N. *et al.* [PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy](https://www.zotero.org/google-docs/?GPYbB4) 777
- [and insulin resistance.](https://www.zotero.org/google-docs/?GPYbB4) *Mol. Cell* **4**, 597–609 (1999). 778
- 33. [Waite, L. L., Louie, R. E. & Taylor, R. N. Circulating Activators of Peroxisome](https://www.zotero.org/google-docs/?GPYbB4) 779
- [Proliferator-Activated Receptors Are Reduced in Preeclamptic Pregnancy.](https://www.zotero.org/google-docs/?GPYbB4) *J. Clin. Endocrinol.* 780
- *Metab.* **90**[, 620–626 \(2005\).](https://www.zotero.org/google-docs/?GPYbB4) 781
- 34. Majithia, A. R. *et al.* Prospective functional [classification of all possible missense](https://www.zotero.org/google-docs/?GPYbB4) 782
- variants in PPARG. *Nat. Genet.* **48**[, 1570–1575 \(2016\).](https://www.zotero.org/google-docs/?GPYbB4) 783
- 35. Ellard, S. *et al.* ACGS Best Practice Guidelines [for Variant Classification in Rare Disease](https://www.zotero.org/google-docs/?GPYbB4) 784
- 2020. *ACGS* [\(2020\).](https://www.zotero.org/google-docs/?GPYbB4) 785
- 36. [Wen, J., Zhu, H. & Leung, P. C. K. Gonadal steroids regulate the expression of](https://www.zotero.org/google-docs/?GPYbB4) 786
- [aggrecanases in human endometrial stromal cells in vitro.](https://www.zotero.org/google-docs/?GPYbB4) *J. Cell. Mol. Med.* **17**, 1325–1334 [\(2013\).](https://www.zotero.org/google-docs/?GPYbB4) 787 788
- 37. [Namli Kalem, M., Kalem, Z., Bakirarar, B. & Demircan, K. Adamts 1, 4, 5, 8, and 9 in](https://www.zotero.org/google-docs/?GPYbB4) Early Pregnancies. *[Fetal Pediatr. Pathol.](https://www.zotero.org/google-docs/?GPYbB4)* **36**, 387–399 (2017). 789 790
- 38. [Qu, H. & Khalil, R. A. Role of ADAM and ADAMTS disintegrin and metalloproteinases in](https://www.zotero.org/google-docs/?GPYbB4) 791
- [normal pregnancy and preeclampsia.](https://www.zotero.org/google-docs/?GPYbB4) *Biochem. Pharmacol.* **206**, 115266 (2022). 792
- 39. [Tatar, M., Uslu, S. & Öner, J. Expression of placental growth factor and a disintegrin and](https://www.zotero.org/google-docs/?GPYbB4) 793
- [metalloprotease with a thrombospondin type motifs 1-4-8 during the three trimesters of rat](https://www.zotero.org/google-docs/?GPYbB4) 794
- [pregnancy at the maternal-fetal interface.](https://www.zotero.org/google-docs/?GPYbB4) *Anat. Histol. Embryol.* **52**, 805–814 (2023). 795
- 40. Kanai-Azuma, M. *et al.* Nrk: a murine X-linked [NIK \(Nck-interacting kinase\)-related](https://www.zotero.org/google-docs/?GPYbB4) 796
- [kinase gene expressed in skeletal muscle.](https://www.zotero.org/google-docs/?GPYbB4) *Mech. Dev.* **89**, 155–159 (1999). 797
- 41. [Nakano, K., Yamauchi, J., Nakagawa, K., Itoh, H. & Kitamura, N. NESK, a member of](https://www.zotero.org/google-docs/?GPYbB4) 798
- [the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is](https://www.zotero.org/google-docs/?GPYbB4) 799
- [expressed during the late stages of embryogenesis.](https://www.zotero.org/google-docs/?GPYbB4) *J. Biol. Chem.* **275**, 20533–20539 800
- [\(2000\).](https://www.zotero.org/google-docs/?GPYbB4) 801
- 42. Denda, K. *et al.* Nrk, an X-linked protein kinase [in the germinal center kinase family, is](https://www.zotero.org/google-docs/?GPYbB4) 802

- [required for placental development and fetoplacental induction of labor.](https://www.zotero.org/google-docs/?GPYbB4) *J. Biol. Chem.* **286**, 803
- [28802–28810 \(2011\).](https://www.zotero.org/google-docs/?GPYbB4) 804
- 43. [Morioka, Y., Nam, J.-M. & Ohashi, T. Nik-related kinase regulates trophoblast](https://www.zotero.org/google-docs/?GPYbB4) 805
- [proliferation and placental development by modulating AKT phosphorylation.](https://www.zotero.org/google-docs/?GPYbB4) *PloS One* **12**, 806
- [e0171503 \(2017\).](https://www.zotero.org/google-docs/?GPYbB4) 807
- 44. Zeng, F. *et al.* Associations between nitric oxide [synthase 3 gene polymorphisms and](https://www.zotero.org/google-docs/?GPYbB4) 808
- [preeclampsia risk: a meta-analysis.](https://www.zotero.org/google-docs/?GPYbB4) *Sci. Rep.* **6**, 23407 (2016). 809
- 45. Honigberg, M. C. *et al.* Polygenic prediction of [preeclampsia and gestational](https://www.zotero.org/google-docs/?GPYbB4) 810
- hypertension. *Nat. Med.* **29**[, 1540–1549 \(2023\).](https://www.zotero.org/google-docs/?GPYbB4) 811
- 46. [Thanabalasingham, G. & Owen, K. R. Diagnosis and management of maturity onset](https://www.zotero.org/google-docs/?GPYbB4) 812
- [diabetes of the young \(MODY\).](https://www.zotero.org/google-docs/?GPYbB4) *BMJ* **343**, d6044 (2011). 813
- 47. [Murray, P. G. & Clayton, P. E. Disorders of Growth Hormone in Childhood. in](https://www.zotero.org/google-docs/?GPYbB4) *Endotext* 814
- [\(eds. Feingold, K. R. et al.\) \(MDText.com, Inc., South Dartmouth \(MA\), 2000\).](https://www.zotero.org/google-docs/?GPYbB4) 815
- 48. Barrios, V. *et al.* Pregnancy-Associated Plasma [Protein \(PAPP\)-A2 in Physiology and](https://www.zotero.org/google-docs/?GPYbB4) 816
- Disease. *Cells* **10**[, 3576 \(2021\).](https://www.zotero.org/google-docs/?GPYbB4) 817
- 49. Overgaard, M. T. *et al.* Pregnancy-associated Plasma [Protein-A2 \(PAPP-A2\), a Novel](https://www.zotero.org/google-docs/?GPYbB4) 818
- [Insulin-like Growth Factor-binding Protein-5 Proteinase.](https://www.zotero.org/google-docs/?GPYbB4) *J. Biol. Chem.* **276**, 21849–21853 819
- [\(2001\).](https://www.zotero.org/google-docs/?GPYbB4) 820
- 50. Tóth, E. *et al.* Decreased Expression of Placental [Proteins in Recurrent Pregnancy Loss:](https://www.zotero.org/google-docs/?GPYbB4) 821
- [Functional Relevance and Diagnostic Value.](https://www.zotero.org/google-docs/?GPYbB4) *Int. J. Mol. Sci.* **25**, 1865 (2024). 822
- 51. [Hattersley, A. T. & Tooke, J. E. The fetal insulin hypothesis: an alternative explanation of](https://www.zotero.org/google-docs/?GPYbB4) 823
- [the association of low birthweight with diabetes and vascular disease.](https://www.zotero.org/google-docs/?GPYbB4) *Lancet Lond. Engl.* 824
- **353**[, 1789–1792 \(1999\).](https://www.zotero.org/google-docs/?GPYbB4) 825
- 52. [Rother, K. I. & Accili, D. Role of insulin receptors and IGF receptors in growth and](https://www.zotero.org/google-docs/?GPYbB4) 826
- development. *Pediatr. Nephrol.* **14**[, 558–561 \(2000\).](https://www.zotero.org/google-docs/?GPYbB4) 827
- 53. Gardner, E. J. *et al.* Damaging missense variants [in IGF1R implicate a role for IGF-1](https://www.zotero.org/google-docs/?GPYbB4) 828

[resistance in the etiology of type 2 diabetes.](https://www.zotero.org/google-docs/?GPYbB4) *Cell Genomics* **2**, None (2022). 829

- 54. Solomon-Zemler, R. *et al.* A novel heterozygous [IGF-1 receptor mutation associated with](https://www.zotero.org/google-docs/?GPYbB4) 830
- hypoglycemia. *Endocr. Connect.* **6**[, 395–403 \(2017\).](https://www.zotero.org/google-docs/?GPYbB4) 831
- 55. Thompson, W. D. *et al.* Fetal alleles predisposing [to metabolically favorable adiposity are](https://www.zotero.org/google-docs/?GPYbB4) 832
- [associated with higher birth weight.](https://www.zotero.org/google-docs/?GPYbB4) *Hum. Mol. Genet.* **31**, 1762–1775 (2022). 833
- 56. Bianco, M. E. *et al.* Hyperglycemia and Adverse [Pregnancy Outcome Follow-Up Study:](https://www.zotero.org/google-docs/?GPYbB4) 834
- [newborn anthropometrics and childhood glucose metabolism.](https://www.zotero.org/google-docs/?GPYbB4) *Diabetologia* **64**, 561–570 835
- [\(2021\).](https://www.zotero.org/google-docs/?GPYbB4) 836
- 57. Adams, M. *et al.* [Activators of peroxisome proliferator-activated](https://www.zotero.org/google-docs/?GPYbB4) receptor gamma have 837
- [depot-specific effects on human preadipocyte differentiation.](https://www.zotero.org/google-docs/?GPYbB4) *J. Clin. Invest.* **100**, 3149–3153 838
- [\(1997\).](https://www.zotero.org/google-docs/?GPYbB4) 839
- 58. Altshuler, D. *et al.* [The common PPARgamma Pro12Ala](https://www.zotero.org/google-docs/?GPYbB4) polymorphism is associated with [decreased risk of type 2 diabetes.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Genet.* **26**, 76–80 (2000). 840 841
- 59. Udler, M. S. *et al.* Type 2 diabetes genetic loci [informed by multi-trait associations point](https://www.zotero.org/google-docs/?GPYbB4) 842
- [to disease mechanisms and subtypes: A soft clustering analysis.](https://www.zotero.org/google-docs/?GPYbB4) *PLOS Med.* **15**, e1002654 [\(2018\).](https://www.zotero.org/google-docs/?GPYbB4) 843 844
- 60. Liu, X. *et al.* Variants in the fetal genome near [pro-inflammatory cytokine genes on 2q13](https://www.zotero.org/google-docs/?GPYbB4) [associate with gestational duration.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Commun.* **10**, 3927 (2019). 845 846
- 61. [Gulcher, J. R., Kristjánsson, K., Gudbjartsson, H. & Stefánsson, K. Protection of privacy](https://www.zotero.org/google-docs/?GPYbB4) 847
- [by third-party encryption in genetic research in Iceland.](https://www.zotero.org/google-docs/?GPYbB4) *Eur. J. Hum. Genet. EJHG* **8**, 848
- [739–742 \(2000\).](https://www.zotero.org/google-docs/?GPYbB4) 849
- 62. [Li, H. A statistical framework for SNP calling, mutation discovery, association mapping](https://www.zotero.org/google-docs/?GPYbB4) 850
- [and population genetical parameter estimation from sequencing data.](https://www.zotero.org/google-docs/?GPYbB4) *Bioinforma. Oxf. Engl.* 851
- **27**[, 2987–2993 \(2011\).](https://www.zotero.org/google-docs/?GPYbB4) 852
- 63. McLaren, W. *et al.* [The Ensembl Variant Effect](https://www.zotero.org/google-docs/?GPYbB4) Predictor. *Genome Biol.* **17**, 122 (2016). 853
- 64. Karczewski, K. J. *et al.* The mutational constraint [spectrum quantified from variation in](https://www.zotero.org/google-docs/?GPYbB4) 854

- 141,456 humans. *Nature* **581**[, 434–443 \(2020\).](https://www.zotero.org/google-docs/?GPYbB4) 855
- 65. [Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the](https://www.zotero.org/google-docs/?GPYbB4) 856
- [deleteriousness of variants throughout the human genome.](https://www.zotero.org/google-docs/?GPYbB4) *Nucleic Acids Res.* **47**, 857
- [D886–D894 \(2019\).](https://www.zotero.org/google-docs/?GPYbB4) 858
- 66. Loh, P.-R. *et al.* Efficient Bayesian mixed-model [analysis increases association power in](https://www.zotero.org/google-docs/?GPYbB4) 859
- large cohorts. *Nat. Genet.* **47**[, 284–290 \(2015\).](https://www.zotero.org/google-docs/?GPYbB4) 860
- 67. Bycroft, C. *et al.* The UK Biobank resource with [deep phenotyping and genomic data.](https://www.zotero.org/google-docs/?GPYbB4) 861
- *Nature* **562**[, 203–209 \(2018\).](https://www.zotero.org/google-docs/?GPYbB4) 862
- 68. Mbatchou, J. *et al.* Computationally efficient [whole-genome regression for quantitative](https://www.zotero.org/google-docs/?GPYbB4) 863
- and binary traits. *Nat. Genet.* **53**[, 1097–1103 \(2021\).](https://www.zotero.org/google-docs/?GPYbB4) 864
- 69. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method [for Predicting the Pathogenicity of](https://www.zotero.org/google-docs/?GPYbB4) 865
- [Rare Missense Variants.](https://www.zotero.org/google-docs/?GPYbB4) *Am. J. Hum. Genet.* **99**, 877–885 (2016). 866
- 70. Purcell, S. *et al.* [PLINK: A Tool Set for Whole-Genome](https://www.zotero.org/google-docs/?GPYbB4) Association and 867
- [Population-Based Linkage Analyses.](https://www.zotero.org/google-docs/?GPYbB4) *Am. J. Hum. Genet.* **81**, 559–575 (2007). 868
- 71. Hawkes, G. *et al.* Genetic evidence that high BMI [in childhood has a protective effect on](https://www.zotero.org/google-docs/?GPYbB4) 869
- [intermediate diabetes traits, including measures of insulin sensitivity and secretion, after](https://www.zotero.org/google-docs/?GPYbB4) 870
- [accounting for BMI in adulthood.](https://www.zotero.org/google-docs/?GPYbB4) *Diabetologia* **66**, 1472–1480 (2023). 871
- 72. Boughton, A. P. *et al.* LocusZoom.js: interactive [and embeddable visualization of genetic](https://www.zotero.org/google-docs/?GPYbB4) 872
- [association study results.](https://www.zotero.org/google-docs/?GPYbB4) *Bioinforma. Oxf. Engl.* **37**, 3017–3018 (2021). 873
- 73. [Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package](https://www.zotero.org/google-docs/?GPYbB4) 874
- [for gene list functional enrichment analysis and namespace conversion toolset g:Profiler.](https://www.zotero.org/google-docs/?GPYbB4) 875
- *F1000Research* **9**[, ELIXIR-709 \(2020\).](https://www.zotero.org/google-docs/?GPYbB4) 876
- 74. Kong, A. *et al.* Detection of sharing by descent, [long-range phasing and haplotype](https://www.zotero.org/google-docs/?GPYbB4) 877
- imputation. *Nat. Genet.* **40**[, 1068–1075 \(2008\).](https://www.zotero.org/google-docs/?GPYbB4) 878
- 75. Gudbjartsson, D. F. *et al.* Large-scale whole-genome [sequencing of the Icelandic](https://www.zotero.org/google-docs/?GPYbB4) 879
- population. *Nat. Genet.* **47**[, 435–444 \(2015\).](https://www.zotero.org/google-docs/?GPYbB4) 880

- 76. Eggertsson, H. P. *et al.* [GraphTyper2 enables population-scale genotyping of structural](https://www.zotero.org/google-docs/?GPYbB4) 881
- [variation using pangenome graphs.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Commun.* **10**, 5402 (2019). 882
- 77. [Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T.](https://www.zotero.org/google-docs/?GPYbB4) 883
- [Accurate, scalable and integrative haplotype estimation.](https://www.zotero.org/google-docs/?GPYbB4) *Nat. Commun.* **10**, 5436 (2019). 884
- 78. Halldorsson, B. V. *et al.* The sequences of 150,119 [genomes in the UK Biobank.](https://www.zotero.org/google-docs/?GPYbB4) *Nature* 885
- **607**[, 732–740 \(2022\).](https://www.zotero.org/google-docs/?GPYbB4) 886
- 79. Mirshahi, U. L. *et al.* Reduced penetrance [of MODY-associated HNF1A/HNF4A variants](https://www.zotero.org/google-docs/?GPYbB4) 887
- [but not GCK variants in clinically unselected cohorts.](https://www.zotero.org/google-docs/?GPYbB4) *Am. J. Hum. Genet.* **109**, 2018–2028 888
- [\(2022\).](https://www.zotero.org/google-docs/?GPYbB4) 889